

FMDA 31rs Annual Conference and Trade Show  
Best Practices in the Post-Acute and Long-term Care Continuum

**Best Practices in Pain Management in PALTC**

**F. Michael Gloth, III, MD, FACP, AGSF**

*Clinical Professor  
Department of Geriatrics, Florida State University College of Medicine*

*Associate Professor of Medicine  
Johns Hopkins University School of Medicine*

*President and CEO, AMDG Naples 100 Senior Concierge and Consulting, LLC*



1

---

---

---

---

---

---

---

---

F. Michael Gloth, III, MD



**This presenter gets royalties from Handbook of Pain Relief in Older Adults.**

“The winning combination of overview and details from current evidence-based medicine will make this handbook attractive to all pain professionals as well as to other professional communities in the health care system, such as nursing staff in hospitals and facilities for the elderly.”

*Matthias Karst, MD, PhD JAMA, May 4, 2011—Vol 305, No. 17*

2

---

---

---

---

---

---

---

---

**Other Resources**

- **Revised Beer’s Criteria**  
(<https://geriatricscareonline.org/ProductAbstract/american-geriatrics-society-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults/CL001>)
- **Gloth FM. (Ed). Handbook of Pain Relief in Older Adults. 2nd Edition. Springer Publishing, New York, NY, 2011**  
(<http://dx.DOI.org/10.1007/978-1-60761-618-4>).
- **Federation of State Medical Boards Policy**  
([https://www.fsmb.org/siteassets/advocacy/policies/opioid\\_guidelines\\_as\\_adopted\\_april-2017\\_final.pdf](https://www.fsmb.org/siteassets/advocacy/policies/opioid_guidelines_as_adopted_april-2017_final.pdf))
- [www.cdc.gov/drugoverdose/prescribing/guideline.html](http://www.cdc.gov/drugoverdose/prescribing/guideline.html)

3

---

---

---

---

---

---

---

---

### Objectives

- Address Epidemiology
- Guidelines
- Educate about Opioid Issues
  - Addiction
  - Diversion
  - Additional Concerns
- Prescribing, E-prescribing, & Discontinuing

---

---

---

---

---

---

---

---

4

### Pain is inadequately treated

- 25-50% of older adults suffer from pain that interferes with daily activities
- 45-80% in nursing home residents have pain
- Age > 70 years is the number one risk factor for inadequate pain management

---

---

---

---

---

---

---

---

5

### Cost of Chronic Pain

- **Chronic Pain affects 116 million U.S. Adults**
- **Annual U.S. economic costs for chronic pain is \$560-630 Billion Dollars!**

IOM Report 2011: [http://books.nap.edu/openbook.php?record\\_id=13172&page=1](http://books.nap.edu/openbook.php?record_id=13172&page=1) accessed 7/1/2011

---

---

---

---

---

---

---

---

6

**By the Numbers**

- Each year between 15-20% of the US population experiences acute pain
- Chronic pain affects approximately 30% of the population annually
- **PAIN IS THE MOST COMMON REASON PATIENTS SEEK MEDICAL ATTENTION**

---

---

---

---

---

---

---

---

7

**AGS Guidelines for the Management of Persistent Pain in Older Persons**

- **Pain not a normal part of aging**
- **Assessment & Management**
- **Health System Barriers**
  - Administrative
  - Regulatory
    - Revise Regulations that have created barriers
  - QI

J Am Geriatr Soc. 2009; 37 (8) 1331-46.

---

---

---

---

---

---

---

---

8

**JCAHO Standards for Pain Management**

- Recognize patients' rightst to appropriate pain management
- Screen for presence and intensity of pain
- Ereassess pain regularly
- Ensure staff competency in pain assessment and management
- Educate pts and family about effectic pain management
- Address patient needs for pain management in discharge planning
- Maintain pain control performance improvement plan

[www.jcaho.org/standar/pm\\_mpfrm.html](http://www.jcaho.org/standar/pm_mpfrm.html)

---

---

---

---

---

---

---

---

9

### Reasons for Inadequate Pain Management

Physician Reasons

- Insufficient Assessment (>70%)
- Fear of using some medication, esp. opioids (>60%)
- Inadequate knowledge (>50%)

Patient Reasons

- Inadequate Reporting
- Fear of stigma of opioids

---

---

---

---

---

---

---

---

10

### Wong-Baker FACES Pain Rating Scale



0 1 2 3 4 5

No hurt Hurts little bit Hurts little more Hurts even more Hurts whole lot Hurts worst

(Wong DL, Hockenberry-Eaton M, Wilson D, et al. *Whaley & Wong's Nursing Care of Infants and Children*. 6th ed. St Louis, MO: Mosby-Year Book, Inc; 1999)

---

---

---

---

---

---


---

---

11

### Visual Analogue Scale (VAS)

No pain Pain as bad as it could possibly be



10 cm

(AHCPR 1994)

---

---

---

---

---

---

---

---

12

## Pain Scales

- In a study of 129 subjects with MMSE<11 (mean age 84 y.o.)...
- > a third of these severely demented individuals couldn't comprehend the verbal, horizontal visual, or faces scale

Pautex S, Michon A, Guedina M et al. Pain in Severe Dementia: Self-Assessment or Observational Scales. *J Am Geriatr Soc.* 2006; 54: 1040-5.

13

---

---

---

---

---

---

---

---

## Modified Functional Pain Scale

- **0 No Pain**
- **2 Tolerable (Doesn't interfere with activities)**
- **4 Tolerable (Interferes with some activities)**
- **6 Intolerable (Able to use phone, TV, or read)**
- **8 Intolerable (Unable to use phone, TV, or read)**
- **10 Intolerable (Unable to verbally communicate)**

Gloth et al. *J Am Med Dir Assoc.* 2001; 2(3): 110-114.

14

---

---

---

---

---

---

---

---

## The Functional Pain Scale

Scale	Relative Efficiency	Standardized Response Means	Effect Size	Paired t-test	Rank (Resp. Index)
FPS	1.00	0.29	0.29 0.0054	2.85	1(7)
VAS	0.32	0.46	0.47 0.04	2.14	2(12)
PPI	0.36	0.25	0.25 0.02	2.21	3(13)
MPQ	0.30	0.22	0.21 0.037	2.11	4(19)
VNS	0.18	0.25	0.22 0.067	1.87	5(24)

Legend: FPS = Functional Pain Scale; VAS = Visual Analog Scale; PPI = Present Pain Intensity; MPQ = McGill Pain Questionnaire-Short Form; VNS = Visual Numerical Pain Scale.

Gloth FM III, Scheve AA, Stober CV, Chow S, Prosser J. The Functional Pain Scale: reliability, validity, and responsiveness in an elderly population. *J Am Med Dir Assoc.* 2001;2(3):110-114.

15

---

---

---

---

---

---

---

---

### Assessing Analgesia in Patients with Limited Ability to Communicate

- Behavioral observation is necessary to make a judgment about pain intensity
  - Facial expressions
    - bracing, guarding, distorted postures, avoidance of activity
  - Movement patterns
    - moans, cries, respiratory pattern
  - Reports of significant others
    - partner, spouse, child

Hadjistavropoulos T, von Baeyer C, Craig KD. Pain assessment in persons with limited ability to communicate. In: Turk DC, Melzack R, eds. *Handbook of Pain Assessment*. 2nd ed. NY, NY: Guilford; 2001:134-152.

16

---

---

---

---

---

---

---

---

### Caregiver Assessment



"One last thing, Doc. My wife wants you to look at the rash she's been treating on my back!"

17

---

---

---

---

---

---

---

---

### Pain

- Nociception (A-delta vs C fibers, opioid receptors)
- Psychological (Secondary Gain, Depression, Mental Focus, Prior Experience, & Anxiety)

18

---

---

---


---

---

---

---

---



19

---

---

---


---

---

---

---

---



20

---

---

---

---

---

---

---

---

### Opioid, NMDA, & GABA Receptors

- $\mu$  – analgesia, miosis, respiratory depression, and euphoria
- $\kappa$  – analgesia, miosis, sedation, and psychotomimetic activity
- $\delta$  – analgesia, miosis, and hypotension
- N-methyl-D-aspartate (NMDA)
- Gamma aminobutyric acid (GABA)

21

---

---

---


---

---

---

---

---



22

---

---

---

---

---

---

---

---

---

---

## Pain Management

- Nonpharmacological
  - Cold, Heat, PT/OT, Exercise
  - TENS, Acupuncture
  - Radiation
  - Blocks, Relaxation, Hypnotism, Biofeedback, Massage, Vibration, Magnets...

23

---

---

---

---

---


---

---

---

---

---



24

---

---

---

---

---

---

---

---

---

---



25

---

---

---

---

---

---

---

---

### Bupivacaine as pre-emptive analgesia in third molar surgery: Randomised controlled trial

- 45 patients who had bilateral impacted third molars removed
- Bupivacaine was injected on one side, the other side acting as control
- VAS
- Significant reduction ( $p = 0.05$ ) in postoperative pain on the injected side at 6, 12, and 72 h and an overall reduction in pain up to 7 days

M. Sharif Nayyara and C. Yates. British Journal of Oral and Maxillofacial Surgery Volume 44, Issue 6, December 2006, Pages 501-503

26

---

---

---

---


---

---

---

---

### Isobolographic Analysis



27

---

---

---


---

---

---

---

---



---

---

---

---


---

---

---

---

28



---

---

---

---

---

---

---

---

29

### Vitamin D Deficiency & Pain

- **Osteomalacia (Deep musculoskeletal pain)**
- **Vitamin D Deficiency Pain Syndrome (Pain with superficial light pressure, pressure sores painful)**
- **Fractures**

Gloth et al. *Arch Intern Med.* 1991; 151: 1662-1664.

---

---

---

---

---

---

---

---

30

### Metastatic Bone Pain Management

• **Non Opioids**

- NSAID's COX-2
- Bisphosphonates (pamidronate, zoledronic acid, alendronate, risedronate, ibandronate)
- Radionuclides (strontium 89, samarium 153)

Gloth III FM. The use of a bisphosphonate (etidronate) to improve metastatic bone pain in three hospice patients. Clin J Pain. 1995; 11: 333-5.

31

---

---

---

---

---

---

---

---

---

---

### Other agents (may augment opioid response, especially, in neuropathy)

- **Gabapentin and Pregabalin in neuropathic pain (such pain rarely responds adequately to opioids alone)**
  - an FDA indication for post-herpetic neuralgia.
- **Immunize against pain V-Z vaccine**
- **Duloxetine and some Tricyclic Antidepressants**
  - addressing both neuropathic pain and depression, which commonly accompanies chronic pain

Cunningham AL, Lal H, Kovac M, et al, for the ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. *N Engl J Med.* 2016;375(11):1019-1032.  
Lal H, Cunningham AL, Godeaux O, et al, for the ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. *N Engl J Med.* 2015;372(22):2087-2096

32

---

---

---

---

---

---

---

---

---

---

### Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS) Bayesian Adaptive Comparative Effectiveness Randomized Trial

“Conclusions and Relevance: ... nortriptyline and duloxetine outperformed pregabalin and mexiletine when pain reduction and undesirable adverse effects are combined to a single end point.”

33

---

---

---

---

---

---

---

---

---

---

### Duloxetine for Chronic Pain in OA

- Two 13-week placebo-controlled RCTs demonstrated significant efficacy for pain, physical function and patient global assessment of improvement
- Could be used either alone or as adjunctive therapy in patients taking oral NSAIDs and/or opioid analgesics
- No new safety signals in OA patients
- FDA approved for indication of chronic musculoskeletal pain

Chappell AS et al: Pain 2009;146:253-60 and Pain Pract 2011;11:33-41.

34

---

---

---

---

---

---

---

---

### Opioids

- Short-acting
  - Morphine
  - Codeine
  - Hydrocodone
  - Oxycodone
  - Hydromorphone
  - Oxymorphone
  - Fentanyl

C → M



35

---

---

---

---

---

---

---

---

### Pain Management

- Opioids
  - Morphine CR
  - Oxycodone CR
  - Oxymorphone CR
  - Hydrocodone CR
  - Hydromorphone CR
  - Fentanyl
  - Buprenorphine
  - Tapentadol ER

36

---

---

---

---

---

---

---

---

### Opioids - Fentanyl Patch

- 18-hour reservoir
- 12-hour delay in onset with new patch
- Increased absorption with fever (heat)
- Deaths in opioid-naïve patients

---

---

---

---

---


---

---

---

37

### Equianalgesic Conversions



---

---

---

---

---

---

---

---

38

### Changing Role of Opiate Analgesics

- Controversial in the management of chronic non-cancer pain (CNCP)
- Reluctance among practitioners
- In the last decade, the APS, AAPM and AGS advocated for more and better use of opiate analgesics in the management of CNCP
- Pain as the "fifth vital sign" raised awareness and increased utilization
- About 20 years ago the public felt that physicians were not adequately treating pain with narcotics. *Malpractice suits were filed and won for under treatment resulting in a \$15 million verdict in 1991 (James cases, North Carolina) and \$1.5 million in the Chin case (1998, California)*

---

---

---

---

---

---

---

---

39

***Under treatment was the theme***

- A joint statement from 21 health care organizations and the Drug Enforcement Agency, October 23, 2001
- *“Under-treatment of pain is a serious problem in the United States, including pain among patients with chronic conditions and those who are critically ill or near death”*
- *“Effective pain management is an integral and important aspect of quality medical care, and pain should be treated aggressively”*
- *“For many patients, opiate analgesics, when used as recommended by established pain management guidelines, are the most effective way to treat their pain, and often the only treatment option that provides significant relief.”*

---

---

---

---

---

---

---

---

40

FEDERATION OF STATE MEDICAL  
BOARDS OF THE UNITED STATES, INC.  
*Model Guidelines for the Use of Controlled  
Substances for the Treatment of Pain*

- Evaluation of the Patient
- Treatment Plan
- Informed Consent and Agreement for Treatment
- Periodic Review
- Consultation
- Medical Records
- Compliance with Controlled Substances Laws and Regulations

FSMB. Model Policy for the Use of Controlled Substances for the Treatment of Pain. J Med Licensure Discipline. 2005. 91:31-5; www.fsmb.org

---

---

---

---

---

---

---

---

41

**Things have Changed**

- **A spike in opiate prescriptions and overdose deaths has lead to public outcry and government intervention.**
- **Western Virginia Oxycontin deaths**
- **State Level:** “Pill Mills” in south Florida resulted in 2012 Florida Statute 456.44 on Controlled Substance Prescribing
- **Federal Level:** CDC Guidelines for opiate prescribing for Chronic Pain

---

---

---

---

---

---

---

---

42

### 2012 Florida Legal Requirements for Controlled Substance Prescribing

- Physician must designate themselves as a controlled substance practitioner and
- Have written treatment plan and
- Have written controlled substance agreement and
- See patient at least once every three months and
- Meet strict medical record documentation and
- Refer patients with signs of substance abuse to pain management

<https://www.mpp.org/states/florida/>

43

---

---

---

---

---

---

---

---

---

---

### Risk Factors for Opioid-Related Aberrant Behaviors

- Family history of substance abuse
  - Alcohol, illegal drugs, prescription drugs
    - - Prescription drug abuse history carries greater risk
- Personal history of substance abuse
  - Alcohol, illegal drugs, prescription drugs
    - - Prescription drug abuse history carries greater risk
- Age 16 to 45 years
- History of preadolescent sexual abuse
  - Increases risk for women
- Psychological disease
  - Attention deficit disorder (ADD) or depression
    - - ADD carries higher risk

44

---

---

---

---

---

---

---

---

---

---

### Opioids in Persistent Pain Recommendations

- X. Clinicians should anticipate, assess for, and identify potential opioid-associated adverse effects.

(moderate quality of evidence, strong recommendation)

- Tolerance develops to many symptoms within days
- Constipation still requires:
  - peripheral opioid antagonists (*methylnaltrexone, naloxegol, naldemadine, alvimopan*)
  - hydration
  - bulk fiber (only if hydration can be maintained)
  - activity
  - senna (others tegaserod, lubiprostone, linaclotide)
  - polyethylene glycol, sorbitol (20cc 70% BID < 3 d's).



Thomas J. Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. *N Engl J Med*. 2008;358:2332-2343. See also *N Engl J Med* 2014;370:2387-96.

45

---

---

---

---

---

---

---

---

---

---

### Opioids for Neuralgia

Treatment of post-herpetic neuralgia

1. Opioids perform as well as tricyclic antidepressants (TCA) for pain relief
2. Opioids and TCA significantly better than placebo (Avoid Amitriptyline and Imipramine in seniors) :
  - 38% opioid and 32% TCA vs. 11% placebo;  $p < 0.001$
3. Patient preference was for opioids:
  - 54% opioids vs 30% TCA;  $p=0.02$

Raja S N; Haythornthwaite J A; Pappagallo M; Clark M R; Trivison T G; Sabeen S; Royall R M; Max M. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002;59(7):1015-21

---

---

---

---

---

---

---

---

---

---

46

### Opioids in Persistent Pain Recommendations (cont'd)

- **XIII. Methadone should be initiated and titrated cautiously only by clinicians well versed in its use and risks. (moderate quality of evidence, strong recommendation)**

**Methadone and Other Opioid Deaths, 1999-2004**

Year	Methadone-Related Deaths	Other Opioid Deaths
1999	784	2,757
2000	988	2,932
2001	1,450	3,484
2002	2,360	4,431
2003	2,974	4,877
2004	3,849	5,242

National Drug Intelligence Center. Methadone Diversion, Abuse, and Misuse: Deaths Increasing at Alarming Rate. November 16, 2007. Source: National Center for Health Statistics.

---

---

---

---

---

---

---

---

---

---

47

### FSMB: Breaches

- Inadequate attention to initial assessment
- Inadequate monitoring
- Inadequate attention to patient education and informed consent
- Unjustified dose escalation without adequate attention to risks or alternative treatments:
- Not making use of available tools for risk mitigations

---

---

---

---

---

---


---

---

---

---

48



49

---

---

---

---

---

---

---

---



50

---

---

---


---

---

---

---

---



51

---

---

---

---

---

---

---

---

### ASSESSING RISK AND ADDRESSING HARMS OF OPIOID USE

- Evaluate risk factors for opioid-related harms
- Check PDMP for high dosages and prescriptions from other providers
- Use urine drug testing to identify prescribed substances and undisclosed use
- Avoid concurrent benzodiazepine and opioid prescribing
- Arrange treatment for opioid use disorder if needed

[www.cdc.gov/drugoverdose/prescribing/guideline.html](http://www.cdc.gov/drugoverdose/prescribing/guideline.html)

52

---

---

---

---

---

---

---

---

### Tapering and D/C'ing ER/LA Opioids

- Titrate downward to prevent signs and symptoms of withdrawal in the physically dependent patient
  - Do not abruptly discontinue these products
    - Decrease original dose by 10% per week
- Abrupt discontinuation of chronic opioids may cause withdrawal characterized by:
  - Stomach cramps, diarrhea, rhinorrhea, sweating, elevated heart rate, increased blood pressure, irritability, dysphoria, hyperalgesia, and insomnia

[www.cdc.gov/drugoverdose/prescribing/guideline.html](http://www.cdc.gov/drugoverdose/prescribing/guideline.html)

53

---

---

---

---

---

---

---

---

### CDC Guidelines

- The Guideline is not intended for patients who are in active cancer treatment, palliative care, or end-of-life care.
- Non pharmacologic and non opioid pharmacologic therapy are preferred for chronic pain.
- Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients
- Before starting and periodically during opioid therapy, clinicians should discuss with patients known risks and realistic benefits of opioid therapy and patient and clinician responsibilities for managing therapy.



54

---

---

---

---

---

---

---

---

### Interventional Techniques

- **Proliferative Therapies**
  - **Nerve Blocks**
  - **Facet Denervation**
  - **Intrathecal Pumps**
  - **Dorsal Cord Stimulation**

---

---

---

---

---


---

---

55



### Pain Pentagon®



© 2003 F. Michael Gloth, III, M.D.

---

---

---

---

---

---

---

56

### Summary

- **FPS to help assess pain in seniors**
- **Pre-emptive Analgesia**
- **Synergy**
- **Prevent pain with CR opioids or vaccine**
- **Pain Pentagon**

---

---

---


---

---

---

---

57



58

---

---

---

---

---


---

---

---

---

---



59

---

---

---

---

---

---

---

---

---

---

FMDA 31rs Annual Conference and Trade Show  
Best Practices in the Post-Acute and Long-term Care Continuum

**Best Practices in Pain Management in PALTC**

**F. Michael Gloth, III, MD, FACP, AGSF**

*Clinical Professor  
Department of Geriatrics, Florida State University College of Medicine*

*Associate Professor of Medicine  
Johns Hopkins University School of Medicine*

*President and CEO, AMDG Naples 100 Senior Concierge and Consulting, LLC*

60

---

---

---

---

---

---

---

---

---

---

**References**

- Evidence-Based
  - Quigley C. Hydromorphone for acute and chronic pain, Cochrane Library, Issue 2, 2003.
  - McQuay HJ, et al. Radiotherapy for the palliation of painful bone metastases. Cochrane Library, Issue 2, 2003.
  - Mailis A, Furlan A, Sympathectomy for neuropathic pain, Cochrane Library, Issue 2, 2003.
- Recommended Reading
  - World Health Organization, Cancer pain relief, 2nd Ed., Geneva, 1996.
  - Abraham JL, A Physicians Guide to Pain and Symptom Management in Cancer Patients, J. Hopkins University Press, Baltimore, 2000.

---

---

---

---

---

---

---

---

61

**References**

- AAFP Lecture, Management of Chronic Pain, by Gary I. Levine, MD, FAAFP
- Florida Marijuana Policy Project
- <https://www.mpp.org/states/florida/>
- Images courtesy of Bing image search

---

---

---

---

---

---

---

---

62

**Federal Regulations**  
21 CFR 1306.07

- May treat acute / chronic pain with a Schedule II narcotic in a recovering narcotic – addicted patient
- Federal law or regulations do not restrict the prescribing, dispensing or administering of a narcotic medication to a narcotic–addicted patient for the purpose of alleviating pain, if such prescribing is medical appropriate within standards set by the medical community.
- One must keep good records to document the physician is treating a pain syndrome, not the disease of narcotic addiction.

---

---

---

---

---

---

---

---

63

### More from the CDC

- When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids
- When opioids are started, clinicians should prescribe the lowest effective dosage.
- Long-term opioid use often begins with treatment of acute pain.
- Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain



64

---

---

---

---

---

---

---

---

### And More

- Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms.
- Clinicians should review the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP) data to determine whether the patient is receiving opioid dosages or dangerous combinations that put him or her at high risk for overdose

65

---

---

---

---

---

---

---

---

### Yet More



- When prescribing opioids for chronic pain, clinicians should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs.
- Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently whenever possible
- Clinicians should offer or arrange evidence-based treatment (usually medication assisted treatment with buprenorphine or methadone in combination with behavioral therapies) for patients with opioid use disorder

66

---

---

---

---

---

---

---

---

### Marijuana

- Amendment 2 in 2016 vote, signed by Gov. Rick Scott into law in June 2017
- Working on decriminalization from the Federal level (due to Florida Statute 893.13)
- Studies done that show
  - Evidence for clinical benefit in HIV neuropathic pain
  - MS patients report less spasticity



---

---

---

---

---

---

---

---

67

### Marijuana continued

- Three forms available: oils, pills, Vape pen
- No reversal available for overdose (overdose can include psychosis and anxiety symptoms), however no documented deaths from overdose.
- HUGE patient financial burden as no banks allowed to be involved in transactions (due to Federal illegal status). It is a cash only business.

---

---

---

---

---

---

---

---

68

### Marijuana Prescribing

- Prescribing and dispensing are NOT the same thing
- Prescribers must complete training course
- Patient must register on the Office of Compassionate Use website (managed by Moffitt Cancer Center), provide passport photos and receive a treatment card

---

---

---

---

---

---

---

---

69

### Indications for Marijuana

- **Qualifying Disease States**
  - Cancer, HIV/AIDS, Seizure Disorders, Sleep Disorders, Anorexia, Crohn’s Disease, Parkinson’s, Multiple Sclerosis, PTSD, ALS
  - Medical conditions of the same kind or class/comparable to those listed above
  - Any Terminal Condition

---

---

---

---

---

---

---

---

70

### Legal Update 2019

- In 2019, Governor Ron DeSantis signed Senate Bill 182 which repealed the previous ban on smokable medical marijuana. According to Florida’s Office of Medical Marijuana Use:
- “The qualified physician must determine that smoking is an appropriate route of administration for medical marijuana and have the patient sign an updated consent form before placing an order for medical marijuana in a form for smoking for the patient in the Medical Marijuana Use Registry.”
- Medical cannabis patients are now permitted to receive up to 2.5 ounces of whole flower cannabis every 35 days. They may not possess more than 4 ounces at any given time. Patients under the age of 18 must have a terminal disease and receive the additional approval of a pediatrician to receive smokable cannabis

---

---

---

---

---

---

---

---

71

### Take Home Message on Marijuana

- DOH Handout for patients
  - [http://www.floridahealth.gov/programs-and-services/office-of-medical-marijuana-use/patients/\\_documents/ommu-patient.pdf](http://www.floridahealth.gov/programs-and-services/office-of-medical-marijuana-use/patients/_documents/ommu-patient.pdf)
- May be a much better alternative to Opioids
- Expensive
- Lots of hurdles to jump through
- RECREATIONAL Marijuana still illegal
- RAPIDLY CHANGING LANDSCAPE HERE IN FLORIDA

---

---

---

---

---

---

---

---

72

Other Reasons...

- <1% of the thousands of papers published on pain focus on the aging society
- Lack of time in the nursing home for assessment and treatment of pain
- Fear of being labeled a complainer
- Belief that pain is a normal part of aging

Ferrell BA. Ann Intern Med. 1995; 123:681-7  
Weiner DK et al. J Am Geriatr Soc. 2002; 50: 2035-40.

73

---

---

---

---

---

---

---

---

**Pain Management Costs**

- Always consider cost!
  - Individual Costs and Ability to Pay
  - Societal Costs
  - Cheaper per Pill may NOT be less costly
    - If pill is more expensive, but it prevents serious complications associated with ADR's, then overall health care costs may be reduced.

74

---

---

---

---

---

---

---

---